<html>
<head>PUBMED IDs for CD158k</head>
<body bgcolor='#C5F0F2'><h1>CD158k</h1><a href='https://pubmed.ncbi.nlm.nih.gov/16457762/'>[Epidermotropic T cell lymphomas as models for tumor progression].</a> February 7  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/21191411/'>Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.</a> June 1  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/23429988/'>Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis.</a> April 25  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/25044837/'>Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.</a> June 24  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25314094/'>Characterization of the novel Sezary lymphoma cell line BKP1.</a> November 18  2014<br></body></html>
